160 related articles for article (PubMed ID: 34455614)
1. MEX3D is an oncogenic driver in prostate cancer.
Shao L; Wang J; Karatas O; Ittmann M
Prostate; 2021 Nov; 81(15):1202-1213. PubMed ID: 34455614
[TBL] [Abstract][Full Text] [Related]
2. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
[TBL] [Abstract][Full Text] [Related]
3. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN.
Shao L; Wang J; Karatas OF; Feng S; Zhang Y; Creighton CJ; Ittmann M
Oncotarget; 2018 Mar; 9(18):14456-14471. PubMed ID: 29581856
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer.
Nip H; Dar AA; Saini S; Colden M; Varahram S; Chowdhary H; Yamamura S; Mitsui Y; Tanaka Y; Kato T; Hashimoto Y; Shiina M; Kulkarni P; Dasgupta P; Imai-Sumida M; Tabatabai ZL; Greene K; Deng G; Dahiya R; Majid S
Oncotarget; 2016 Oct; 7(42):68371-68384. PubMed ID: 27634912
[TBL] [Abstract][Full Text] [Related]
6. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
7. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
8. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
9. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Carver BS; Tran J; Gopalan A; Chen Z; Shaikh S; Carracedo A; Alimonti A; Nardella C; Varmeh S; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nat Genet; 2009 May; 41(5):619-24. PubMed ID: 19396168
[TBL] [Abstract][Full Text] [Related]
10. Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.
Berger PL; Frank SB; Schulz VV; Nollet EA; Edick MJ; Holly B; Chang TT; Hostetter G; Kim S; Miranti CK
Cancer Res; 2014 Jun; 74(12):3357-68. PubMed ID: 24762396
[TBL] [Abstract][Full Text] [Related]
11. DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1.
Hong Z; Zhang W; Ding D; Huang Z; Yan Y; Cao W; Pan Y; Hou X; Weroha SJ; Karnes RJ; Wang D; Wu Q; Wu D; Huang H
Mol Cell; 2020 Sep; 79(6):1008-1023.e4. PubMed ID: 32871104
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
Mao N; Gao D; Hu W; Gadal S; Hieronymus H; Wang S; Lee YS; Sullivan P; Zhang Z; Choi D; Rosen N; Sawyers CL; Gopalan A; Chen Y; Carver BS
Cancer Res; 2020 Apr; 80(7):1428-1437. PubMed ID: 32015092
[TBL] [Abstract][Full Text] [Related]
13. Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S; Lutz J; Hube-Magg C; Kluth M; Simon R; Höflmayer D; Burandt E; Tsourlakis MC; Sauter G; Büscheck F; Wilczak W; Steurer S; Schlomm T; Huland H; Graefen M; Haese A; Heinzer H; Jacobsen F; Hinsch A; Poos A; Oswald M; Rippe K; König R; Schroeder C
Prostate; 2019 Feb; 79(3):302-311. PubMed ID: 30430607
[TBL] [Abstract][Full Text] [Related]
14. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
15. A novel approach to identify driver genes involved in androgen-independent prostate cancer.
Schinke EN; Bii V; Nalla A; Rae DT; Tedrick L; Meadows GG; Trobridge GD
Mol Cancer; 2014 May; 13():120. PubMed ID: 24885513
[TBL] [Abstract][Full Text] [Related]
16. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
17. In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun.
Riedel M; Berthelsen MF; Cai H; Haldrup J; Borre M; Paludan SR; Hager H; Vendelbo MH; Wagner EF; Bakiri L; Thomsen MK
Oncogene; 2021 Apr; 40(13):2437-2447. PubMed ID: 33674748
[TBL] [Abstract][Full Text] [Related]
18. Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3.
Lin Y; Zhan M; Xu B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7663-7677. PubMed ID: 37000263
[TBL] [Abstract][Full Text] [Related]
19. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
20. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
